1.3.1.21: 7-dehydrocholesterol reductase
This is an abbreviated version!
For detailed information about 7-dehydrocholesterol reductase, go to the full flat file.
Word Map on EC 1.3.1.21
-
1.3.1.21
-
smith-lemli-opitz
-
malformation
-
cyp2r1
-
anomaly
-
25-hydroxyvitamin
-
syndactyly
-
d-related
-
desmosterol
-
8-dehydrocholesterol
-
dhcr24
-
genitalia
-
oxysterols
-
holoprosencephaly
-
rsh
-
ecdysteroids
-
cholesterogenic
-
medicine
-
diagnostics
-
25-hydroxylase
-
trazodone
-
aripiprazole
-
ebp
-
hmgcs1
- 1.3.1.21
-
smith-lemli-opitz
- malformation
- cyp2r1
- anomaly
-
25-hydroxyvitamin
-
syndactyly
-
d-related
- desmosterol
- 8-dehydrocholesterol
- dhcr24
-
genitalia
- oxysterols
- holoprosencephaly
- rsh
- ecdysteroids
-
cholesterogenic
- medicine
- diagnostics
-
25-hydroxylase
- trazodone
- aripiprazole
- ebp
- hmgcs1
Reaction
Synonyms
3-hydroxysterol DELTA7-reductase, 3beta-hydroxysterol DELTA7-reductase, 3beta-hydroxysterol-DELTA7-reductase, 7-dehydrocholesterol DELTA7 reductase, 7-dehydrocholesterol DELTA7-reductase, 7-DHC reductase, 7-DHCR, Csa7G447780, DAF-36, DELTA5,7-sterol DELTA7-reductase, Des7, Dhcr7, Dhcr7-AS-1, Dhcr7-AS-2, Dhcr7-AS-4, Dwarf5 protein, DWF5, Neverland, Nvd, reductase, 7-dehydrocholesterol, Sterol delta-7-reductase, sterol DELTA7 reductase, sterol DELTA7-reductase
ECTree
Advanced search results
Application
Application on EC 1.3.1.21 - 7-dehydrocholesterol reductase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
diagnostics
medicine
-
enzyme activity measurement can be a tool for prognosis of the Smith-Lemli-Opitz syndrome
diagnostics
-
enzyme activity measurement is useful for distinguishing Smith-Lemli-Opitz syndrome from carrier or unaffected cells, diagnosis of atypical cases, overview
diagnostics
-
enzyme is a key marker of early Leydig cell steroidogenesis, using the technique of differential display RT-PCR
-
mutation apoB38.9 in apolipoprotein B results in a hypobetalipoproteinemia-like phenotype and leads to downregulation of enzyme and several other cholesterogenic enzymes
medicine
-
mutational analysis of the DHCR7 gene in individuals from five families with Smith-Lemli-Opitz syndrome. No single mutation is responsible for the photosensitivity which characterizes Smith-Lemli-Opitz syndrome
medicine
-
Smith-Lemli-Opitz syndrome is caused not only by disruption of the enzymatic role of 7-dehydrocholesterol reductase as a reductase in cholesterol biosynthesis, but may also involve defects in enzyme resulting in derepression of Sonic Hedgehog signaling
medicine
-
a 7-dehydrosterol reductase deficiency is known as Smith-Lemli-Opitz syndrome
medicine
-
although cholesterol synthesis is impaired in both Dhcr7-deficient and lathosterol 5-desaturase-deficient embryonic brain tissues, the synthesis of nonsterol isoprenoids may be increased and thus contribute to Smith-Lemli-Opitz syndrome and lathosterolosis pathology
medicine
-
construction of an adeno-associated virus vector containing the DHCR7 gene and infusion of this vector into mice deficient for the enzyme leads to identification of the introduced DHCR7 gene in liver, expression of mRNA production of a functional enzyme. Evidence of functionality comes from the ability to partially normalize the serum ratio of 7-dehydrocholesterol/cholesterol in treated animals, apparently by increasing cholesterol production with concomitant decrease in the 7-dehydrocholesterol precursor. By five weeks after treatment the mean ratio for 7 animals has fallen to 0.05 while the ratio for untreated littermate controls has risen to 0.14
medicine
-
screening of patients diagnosed for elevated 7-dehydrocholesterol levels identified three individuals affected with Smith-Lemli-Opitz Syndrome, and 22 with elevated 7-dehydrocholesterol levels in the absence of Smith-Lemli-Opitz Syndrome. Seven of these individuals showed no mutation in the gene encoding 7-dehydrocholesterol reductase. The medication history of these individuals revealed aripiprazole and trazodone as common medications to all the false positive results
medicine
in a time-pregnant mouse model where wild-type and Dhcr7+/- embryos are maternally exposed to aripiprazole or vehicle, aripiprazole and its metabolites are transported across the placenta and reach the brain of offspring. Maternal aripiprazole exposure leads to decreased viability of embryos and increased 7-DHC levels, regardless of maternal or offspring Dhcr7 genotype. Dhcr7+/- pups are more vulnerable to maternal aripiprazole exposure than their wild-type littermates, and maternal Dhcr7+/- genotype also exacerbates offspring response to aripiprazole treatment. Both 7-DHC levels and 7-DHC/cholesterol ratio is the highest in Dhcr7+/- pups from Dhcr7+/- mothers exposed to aripiprazole
medicine
-
interaction with endothelial cells for 48 h down-regulates expression of genes in vascular smooth muscle cells controlling rate-limiting steps of the cholesterol biosynthesis such as HMG-CoA reductase, HMG-CoA-synthase-1, 24-dehydrocholesterol reductase and DHCR7. A decrease in the abundance of 24-dehydrocholesterol reductase and lower cholesterol levels in vascular smooth muscle cells cocultured with endothelial cells is observed
medicine
upon DNA and RNA viral infection, macrophages reduce 7-dehydrocholesterol reductase (DHCR7) expression. DHCR7 deficiency or treatment with 7-dehydrocholesterol (7-DHC) can specifically promote phosphorylation of IRF3 and enhance type I interferon production in macrophages. Viral infection or 7-DHC treatment enhances AKT3 expression and activation. Deletion of DHCR7 and the DHCR7 inhibitors including AY9944 and the chemotherapy drug tamoxifen promote clearance of Zika virus and multiple viruses in vitro or in vivo